Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ROR1
REST API REST API
Homo sapiens
ROR1 is differentially expressed in 306 experiments: 171 organism parts: skeletal muscle, adipose tissue, ... (169 more);, 214 disease states: normal, glioblastoma, ... (212 more);, 97 cell types 419 cell lines 36 compound treatments and 76 other conditions.
Synonyms NTRKR1
Orthologs ROR1 (Gallus gallus)   ENSCING00000003415 (Ciona intestinalis)   Ror1 (Rattus norvegicus)   Ror1 (Mus musculus)   ror1 (Danio rerio)   ROR1 (Bos taurus)   ENSCING00000006519 (Ciona intestinalis)   Ror (Drosophila melanogaster)   ror1 (Xenopus laevis)   ROR1 (Canis familiaris)   (Compare orthologs)
InterPro Term Ig_V-set, Ig_sub, Immunoglobulin, Prot_kinase_cat_dom, Ig-like, Ig_sub2, Kringle, Tyr_kinase_rcpt_ROR_subgr, Frizzled_dom, Ig_I-set, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
Gene Ontology Term plasma membrane, protein binding, cytoplasm, membrane, protein tyrosine kinase activity, transmembrane receptor protein tyrosine kinase signaling pathway, ATP binding, transferase activity, transferring phosphorus-containing groups, Wnt-protein binding, integral to plasma membrane, receptor activity, nucleotide binding, kinase activity, protein serine/threonine kinase activity, transmembrane receptor protein tyrosine kinase activity, integral to membrane, protein kinase activity, protein phosphorylation
UniProt Accession Q66K77, A2VCQ3, Q01973
Search EB-eye ENSG00000185483
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-22541, E-GEOD-6573, E-GEOD-7540, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (40 experiments)

Factor Value U/D Experiments
A549
2
E-GEOD-6013, E-GEOD-3202
AGS
2
E-MTAB-37, E-GEOD-15460
MCF-7
2
E-GEOD-20081, E-GEOD-19639
MDA-MB-231
2
E-TABM-420, E-MTAB-62
MDA468
2
E-MEXP-440, E-MTAB-62
MOLT4
2
E-MTAB-37, E-MTAB-62
413 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, ... (49 experiments)

Factor Value U/D Experiments
stromal cell
1
4
E-GEOD-1460, E-GEOD-3998, E-MEXP-2034, E-MEXP-1327, E-GEOD-10797 ... (5 experiments)
1
2
E-TABM-130, E-TABM-145
induced pluripotent stem cell
2
E-GEOD-18147, E-GEOD-18265
endothelial cell
1
2
E-GEOD-3998, E-GEOD-19240, E-GEOD-3920
human embryonic stem cell
1
2
E-GEOD-18265, E-GEOD-18147, E-GEOD-20033
adult native RPE from 78 y.o. donor
1
E-GEOD-18811
91 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-TABM-15, E-GEOD-16363, ... (71 experiments)

Factor Value U/D Experiments
control
3
E-GEOD-21912, E-GEOD-16363, E-GEOD-20168
lung adenocarcinoma
1
3
E-MTAB-62, E-MTAB-37, E-GEOD-2514, E-MEXP-231
head and neck squamous cell carcinoma
2
E-MTAB-62, E-GEOD-6631
prostate carcinoma
2
E-MEXP-2034, E-GEOD-96
chronic lymphocytic leukemia
2
E-GEOD-6691, E-GEOD-2466
gastric carcinoma
2
E-MTAB-37, E-GEOD-2685
208 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-5741, E-GEOD-15205, E-GEOD-1417, E-GEOD-697, ... (19 experiments)

Factor Value U/D Experiments
control
2
E-GEOD-4567, E-GEOD-3284
U0126
1
E-GEOD-697
NaOH
1
1
E-MEXP-2590
camptothecin
1
E-GEOD-1417
phenol
1
E-GEOD-6907
lipopolysaccharide
1
E-MEXP-1958
30 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-4922

Factor Value U/D Experiments
34
2
1
E-GEOD-3494
86 years
1
1
E-GEOD-4922


Age at onset
studied in E-GEOD-21521

Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (9 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

crosslinker and crosslinking wavelength
studied in E-GEOD-21918

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-GEOD-6236, E-GEOD-2666, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138, E-GEOD-21887, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, E-GEOD-361, ... (7 experiments)

Genotype
studied in E-GEOD-1045, E-TABM-1029, E-MEXP-1996, E-GEOD-2466, E-GEOD-17476, ... (13 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-6432, E-MEXP-2657, E-GEOD-20504, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-GEOD-1926, E-MEXP-2069, ... (26 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-17400, E-GEOD-6802

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-5824, E-GEOD-1657, ... (8 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797, E-GEOD-18791

RNAi
studied in E-MEXP-2115, E-MEXP-1509, E-MEXP-101, E-MEXP-548, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-2466, E-GEOD-7307, E-GEOD-16363

Sirna
studied in E-GEOD-21575, E-GEOD-21574

Stimulation
studied in E-GEOD-11886

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.422 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM